RxDoctor Payments Data

Vera Filipovska

Nurse Practitioner · Tobyhanna, PANPI 1457787285

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 34 payments — averaging $35.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$240
  • AstraZeneca$236
  • Lilly USA, LLC$179
  • Exact Sciences$151
  • Medtronic$128
  • Phadia US Inc.$119
  • plus $165 from 8 others

What the payments were for

  • Food & beverage$1,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,142
Medicare patients
71
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$54,870
TrulicityDulaglutide30$38,652
OzempicSemaglutide20$29,471
JardianceEmpagliflozin13$11,420
Atrovent HfaIpratropium Bromide11$5,174
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,476
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,728
Janumet XrSitagliptin Phos/Metformin Hcl11$3,534
Albuterol Sulfate HfaAlbuterol Sulfate94$2,809
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$1,760
Atorvastatin Calcium161$1,685
Potassium Chloride117$1,639
Gabapentin102$1,550
Trazodone Hcl43$1,314
Montelukast Sodium128$1,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$179$38,65230 claims
Novo NordiskOzempic$240$29,47120 claims
Boehringer IngelheimJardiance$29$11,42013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Tobyhanna

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →